$NXTC
NextCure Inc

2023 Q1 Form 10-K Financial Statement

#000155837023002698 Filed on March 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.424M $4.949M $21.71M
YoY Change -5.62% 2.95% 5.53%
% of Gross Profit
Research & Development $11.65M $12.82M $54.20M
YoY Change -22.48% 4.55% 7.98%
% of Gross Profit
Depreciation & Amortization $960.0K $1.007M $4.100M
YoY Change -54.22% -52.12% -4.65%
% of Gross Profit
Operating Expenses $17.07M $17.77M $75.91M
YoY Change -17.81% 4.1% 7.27%
Operating Profit -$17.07M -$75.91M
YoY Change -17.81% 7.27%
Interest Expense $975.0K $471.0K $1.176M
YoY Change 476.92% 256.82% -14.53%
% of Operating Profit
Other Income/Expense, Net $975.0K $1.176M
YoY Change 476.92% -14.53%
Pretax Income -$16.10M -$17.30M -$74.73M
YoY Change -21.87% 2.13% 7.7%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$16.10M -$17.30M -$74.73M
YoY Change -21.87% 2.13% 7.7%
Net Earnings / Revenue
Basic Earnings Per Share -$0.58 -$2.69
Diluted Earnings Per Share -$0.58 -$0.62 -$2.69
COMMON SHARES
Basic Shares Outstanding 27.77M 27.77M 27.74M
Diluted Shares Outstanding 27.77M 27.74M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $145.5M $159.9M $159.9M
YoY Change -27.73% -27.18% -27.18%
Cash & Equivalents $29.97M $26.63M $26.63M
Short-Term Investments $115.5M $133.3M $133.3M
Other Short-Term Assets $3.425M $4.072M $4.072M
YoY Change -54.99% -50.5% -50.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $148.9M $164.0M $164.0M
YoY Change -28.72% -28.02% -28.02%
LONG-TERM ASSETS
Property, Plant & Equipment $11.19M $11.90M $16.91M
YoY Change -15.51% -14.97% 20.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.823M $3.265M $3.265M
YoY Change 391.81% 465.86% 465.86%
Total Long-Term Assets $18.87M $20.18M $20.18M
YoY Change 36.63% 38.5% 38.5%
TOTAL ASSETS
Total Short-Term Assets $148.9M $164.0M $164.0M
Total Long-Term Assets $18.87M $20.18M $20.18M
Total Assets $167.8M $184.2M $184.2M
YoY Change -24.67% -24.02% -24.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.919M $4.270M $4.270M
YoY Change -31.49% 119.88% 119.88%
Accrued Expenses $4.347M $4.857M $4.857M
YoY Change 27.44% 9.17% 9.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $6.266M $9.127M $9.127M
YoY Change -2.46% 38.12% 38.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $872.0K $899.0K $7.504M
YoY Change -63.45% -62.42% 213.71%
Total Long-Term Liabilities $872.0K $899.0K $7.504M
YoY Change -63.45% -62.42% 213.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.266M $9.127M $9.127M
Total Long-Term Liabilities $872.0K $899.0K $7.504M
Total Liabilities $13.59M $16.63M $16.63M
YoY Change 54.23% 84.79% 84.79%
SHAREHOLDERS EQUITY
Retained Earnings -$277.9M -$261.8M
YoY Change 33.82% 39.96%
Common Stock $28.00K $28.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $154.2M $167.5M $167.5M
YoY Change
Total Liabilities & Shareholders Equity $167.8M $184.2M $184.2M
YoY Change -24.67% -24.02% -24.02%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$16.10M -$17.30M -$74.73M
YoY Change -21.87% 2.13% 7.7%
Depreciation, Depletion And Amortization $960.0K $1.007M $4.100M
YoY Change -54.22% -52.12% -4.65%
Cash From Operating Activities -$14.78M -$8.949M -$53.89M
YoY Change -4.32% -33.46% -5.87%
INVESTING ACTIVITIES
Capital Expenditures $248.0K $865.0K $2.116M
YoY Change -18.69% -204.85% -10.34%
Acquisitions
YoY Change
Other Investing Activities $18.37M $5.333M $70.10M
YoY Change 31.15% -152.41% 79.91%
Cash From Investing Activities $18.12M $4.468M $67.98M
YoY Change 32.26% -140.61% 85.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 61.00K 200.0K
YoY Change -100.0% -50.41% -106.13%
NET CHANGE
Cash From Operating Activities -14.78M -8.949M -53.89M
Cash From Investing Activities 18.12M 4.468M 67.98M
Cash From Financing Activities 0.000 61.00K 200.0K
Net Change In Cash 3.343M -4.420M 14.29M
YoY Change -298.4% -81.83% -159.78%
FREE CASH FLOW
Cash From Operating Activities -$14.78M -$8.949M -$53.89M
Capital Expenditures $248.0K $865.0K $2.116M
Free Cash Flow -$15.03M -$9.814M -$56.00M
YoY Change -4.6% -22.26% -6.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.69
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.51
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27744209
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27615977
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26630000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12337000
CY2022Q4 nxtc Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1531000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.nextcure.com/20221231#AccruedAndOtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.nextcure.com/20221231#AccruedAndOtherLiabilitiesCurrent
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27774536
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001661059
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27680997
CY2021Q4 nxtc Fair Values Assets Level1 To Level2 Transfers Amount
FairValuesAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q4 nxtc Fair Values Assets Level1 To Level2 Transfers Amount
FairValuesAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 nxtc Fair Values Assets Level2 To Level1 Transfers Amount
FairValuesAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q4 nxtc Fair Values Assets Level2 To Level1 Transfers Amount
FairValuesAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27774536
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1245
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38905
CY2022 dei Entity Registrant Name
EntityRegistrantName
NextCure, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5231247
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
9000 Virginia Manor Road, Suite 200
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Beltsville
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20705
CY2022 dei City Area Code
CityAreaCode
240
CY2022 dei Local Phone Number
LocalPhoneNumber
399-4900
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
NXTC
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
115500000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27774536
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Baltimore, MD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1376000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-75909000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
133281000
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
207254000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4072000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8226000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
163983000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
227817000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11897000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13992000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5016000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3265000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
577000
CY2022Q4 us-gaap Assets
Assets
184161000
CY2021Q4 us-gaap Assets
Assets
242386000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4270000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1942000
CY2022Q4 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4857000
CY2021Q4 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4666000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9127000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6608000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6605000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
899000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2392000
CY2022Q4 us-gaap Liabilities
Liabilities
16631000
CY2021Q4 us-gaap Liabilities
Liabilities
9000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27774536
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27680997
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
430755000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
421047000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1494000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-663000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-261759000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-187026000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
167530000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
233386000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
184161000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
242386000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-70765000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1176000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54199000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50192000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21710000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20573000
CY2022 us-gaap Operating Expenses
OperatingExpenses
75909000
CY2021 us-gaap Operating Expenses
OperatingExpenses
70765000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-74733000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-69389000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.69
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.51
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27744209
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27615977
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-74733000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-69389000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-831000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1442000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-75564000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70831000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
293721000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10288000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
208000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021 nxtc Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
-1442000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-69389000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
233386000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9508000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
134000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2022 nxtc Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
-831000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-74733000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
167530000
CY2022 us-gaap Profit Loss
ProfitLoss
-74733000
CY2021 us-gaap Profit Loss
ProfitLoss
-69389000
CY2022 nxtc Depreciation Depletion And Amortization And Other
DepreciationDepletionAndAmortizationAndOther
4124000
CY2021 nxtc Depreciation Depletion And Amortization And Other
DepreciationDepletionAndAmortizationAndOther
4177000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3047000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3019000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
9508000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
10288000
CY2022 nxtc Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
356000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-87000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2038000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4928000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2328000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1959000
CY2022 nxtc Increase Decrease In Accrued And Other Current Liabilities
IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
641000
CY2021 nxtc Increase Decrease In Accrued And Other Current Liabilities
IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
178000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1687000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53886000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57283000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
104739000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
195438000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34644000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
156477000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
200000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2116000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2360000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67979000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36601000
CY2021Q3 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-2400000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
66000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
208000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
134000
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
3473000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5000000.0
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3265000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14293000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23947000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12337000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36284000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26630000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12337000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
90000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
162000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6047000
CY2022 nxtc Operating Lease Liabilities Initial Lease Recognition Amount
OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount
7549000
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15560569
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4077192
CY2019Q4 us-gaap Share Price
SharePrice
36.75
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
611578
CY2019Q4 us-gaap Share Price
SharePrice
36.75
CY2019Q4 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
160900000
CY2019Q4 nxtc Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
10300000
CY2019Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000000.0
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p>
CY2022Q4 nxtc Required Reserve Restricted Cash Current
RequiredReserveRestrictedCashCurrent
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </p>
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2022 us-gaap Lease Practical Expedient Use Of Hindsight
LeasePracticalExpedientUseOfHindsight
false
CY2021Q4 nxtc Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
727000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q4 nxtc Accrued Sponsored Research Expense Current
AccruedSponsoredResearchExpenseCurrent
417000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
134775000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1494000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
133281000
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
207917000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
666000
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
207254000
CY2022 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
9000
CY2021 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
57000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
133300000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
91800000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
105930000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
104660000
CY2022Q4 nxtc Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost
28845000
CY2022Q4 nxtc Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
28621000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
134775000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
133281000
CY2022 nxtc Interest Income Non Operating
InterestIncomeNonOperating
700000
CY2021 nxtc Interest Income Non Operating
InterestIncomeNonOperating
1000000.0
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1639000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1751000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28527000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26729000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16630000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12737000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11897000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13992000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4100000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4300000
CY2021Q4 nxtc Accrued Sponsored Research Expense Current
AccruedSponsoredResearchExpenseCurrent
1315000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
518000
CY2022Q4 nxtc Accrued Operating Expenses Current
AccruedOperatingExpensesCurrent
647000
CY2021Q4 nxtc Accrued Operating Expenses Current
AccruedOperatingExpensesCurrent
656000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
105000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
217000
CY2022Q4 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4857000
CY2021Q4 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4666000
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000.0
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
900000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0746
CY2021 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000.0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1032000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1127000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1214000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1355000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1396000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
3295000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9419000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2296000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7123000
CY2016Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1000000.0
CY2019Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5000000.0
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.797
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27774536
CY2022 nxtc Number Of Votes Per Share
NumberOfVotesPerShare
1
CY2022 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9500000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10300000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
14700000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9508000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10288000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
81262000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
57788000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5262179
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4545794
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.034
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.032
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.018
CY2022 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.291
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.285
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49789000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44451000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11395000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8862000
CY2022Q4 nxtc Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
12424000
CY2022Q4 nxtc Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1960000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4389000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3184000
CY2022Q4 nxtc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
1305000
CY2021Q4 nxtc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
1291000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
79724000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57705000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1538000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
83000
CY2021Q4 nxtc Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
83000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1538000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1538000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
83000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
21900000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
180200000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
183100000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
157500000
CY2022Q4 nxtc Deferred Tax Assets Tax Credit Carryforwards Research And Development Federal
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal
11300000
CY2022Q4 nxtc Deferred Tax Assets Tax Credit Carryforwards Research And Development State
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState
100000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
nxtc-20221231_def.xml Edgar Link unprocessable
0001558370-23-002698-index-headers.html Edgar Link pending
0001558370-23-002698-index.html Edgar Link pending
0001558370-23-002698.txt Edgar Link pending
0001558370-23-002698-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nxtc-20221231.xsd Edgar Link pending
nxtc-20221231x10k.htm Edgar Link pending
nxtc-20221231x10k005.jpg Edgar Link pending
nxtc-20221231x10k006.jpg Edgar Link pending
nxtc-20221231x10k007.jpg Edgar Link pending
nxtc-20221231x10k008.jpg Edgar Link pending
nxtc-20221231xex10d27.htm Edgar Link pending
nxtc-20221231xex10d28.htm Edgar Link pending
nxtc-20221231xex10d29.htm Edgar Link pending
nxtc-20221231xex10d30.htm Edgar Link pending
nxtc-20221231xex10d30001.jpg Edgar Link pending
nxtc-20221231xex23d1.htm Edgar Link pending
nxtc-20221231xex31d1.htm Edgar Link pending
nxtc-20221231xex31d2.htm Edgar Link pending
nxtc-20221231xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
nxtc-20221231_lab.xml Edgar Link unprocessable
nxtc-20221231_pre.xml Edgar Link unprocessable
nxtc-20221231x10k_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nxtc-20221231_cal.xml Edgar Link unprocessable